Visterra closes Series A

Visterra, a developer of novel therapeutics to prevent and treat major infectious diseases, has secured $8.1 million in the final closing of its Series A financing round. This financing brings the total proceeds received to date from Series A to $34.2 million. Existing investors – Polaris Venture Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation and Omega Funds – participated in the financing, as well as members of management and employees.

Taris Biomedical Raises $12.5 Million

Taris Biomedical, a specialty pharmaceutical company developing therapies to treat bladder diseases, has raised a fresh $12.5 million in funding from its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. With the new funding, Taris, based in Lexington, Mass., has raised $49.8 million altogether.

With $270m Fund IV, Flagship’s Noubar Afeyan Is Still Bullish on Early Stage Healthcare

Common wisdom is that it’s an unusually tough time to raise capital for early-stage healthcare investing. But Cambridge, Mass.-based Flagship Ventures is demonstrating that it’s possible to buck the trend. This week, the 11-year-old firm announced it has raised $270 million for a fourth fund that will be dedicated principally to early-stage investing and in-house […]

Flagship Ventures Closes Fund IV with $270M

Cambridge, Mass.-based Flagship Ventures has closed its new fund, Flagship Ventures Fund IV L.P., with $270 million in commitments. The firm said it exceeded a $250 million target, and saw participation from pension funds, foundations, fund-of-funds, corporations and individuals. The early-stage investment firm was formed in 2000. It’s previous fund closed in 2007 with $235 million.

Acceleron Pharma Inks $30M

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.

VC-backed Seventh Sense Inks $3.28M Grant

Seventh Sense Biosystems Inc., a Cambridge, Mass.-based developer of technology for decentralized diagnostic testing, has sealed a $3.28 million grant from the Bill & Melinda Gates Foundation. Formed in 2008, the company is backed by investors including Flagship Ventures, Polaris Venture Partners and Third Rock Ventures.

Agios Pharmaceuticals Seals $78M Series C

Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Tangent Medical Closes $4.5M

Arboretum Ventures and Flagship Ventures co-led a $4.5 million Series A round for medical device startup Tangent Medical Technologies Inc. Osage Ventures and several undisclosed angel investors also contributed. Tim Petersen of Arboretum and Harry Wilcox of Flagship have joined Tangent’s board.

VC-Backed Quanterix Adds CEO

Martin Madaus has joined Quanterix Corp. as CEO. The company is a molecular diagnostics firm. Quanterix is backed by ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.

PEHUB Community

Join the 12494 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget